Status: Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.

Participants needed: 150

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Oct 8, 2026Locations: 59

Eligibility criteria

Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional... [+4]

Evidence of lymph node (N2-N3) or metastatic (M1) disease [+5]

Status: Not yet recruiting

Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma

This trial is an open, multicenter, phase II clinical trial evaluating the efficacy and safety of uterostatin capsules (UTD2) combined with doxorubicin and tislelizumab in the treatment of advanced soft tissue sarcoma. A total of 49 participants are planned to be enrolled. Participants who meet the inclusion criteria will receive UTD2 + doxorubicin + tislelizumab. Doxorubicin will be administered for a maximum of 6 cycles. Participants who have no tumor response or a non-progressive disease (CR, PR, SD) after discontinuation of doxorubicin will receive UTD2 + tislelizumab for maintenance treatment. Maintenance treatment will last for a maximum of 2 years, but tislelizumab monotherapy maintenance treatment will last for a maximum of 1 year.

Participants needed: 49

Trial details

Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Beijing Biostar Pharmaceuticals Co., Ltd.Updated: Sep 25, 2026Locations: 1

Eligibility criteria

Fully understand the purpose, content, process of the trial and possible adverse... [+15]

Within the 3 years prior to enrollment, the participant had suffered from other... [+22]

Status: Recruiting

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Participants needed: 39

Trial details

Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Aug 12, 2024Locations: 2

Eligibility criteria

Age 18-75 years. [+7]

Active autoimmune disease or history of autoimmune disease. [+15]